Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 174.73% from the company’s current price.

AQST has been the subject of a number of other reports. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $17.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, Leerink Partners upped their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Stock Up 5.2 %

AQST opened at $3.64 on Friday. The company has a market capitalization of $331.89 million, a PE ratio of -8.09 and a beta of 2.62. The firm has a 50-day simple moving average of $4.74 and a two-hundred day simple moving average of $4.06. Aquestive Therapeutics has a 52 week low of $1.84 and a 52 week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. As a group, sell-side analysts expect that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics in the second quarter worth about $27,000. nVerses Capital LLC purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth $28,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at about $76,000. Financial Advocates Investment Management grew its position in shares of Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after buying an additional 14,000 shares during the last quarter. Finally, Harvey Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $88,000. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.